Evotec (EVO) Competitors $4.11 +0.07 (+1.73%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EVO vs. LEGN, ELAN, CYTK, NUVL, GRFS, TGTX, VKTX, AXSM, KRYS, and OGNShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols TG Therapeutics Viking Therapeutics Axsome Therapeutics Krystal Biotech Organon & Co. Legend Biotech (NASDAQ:LEGN) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations. Does the MarketBeat Community favor LEGN or EVO? Legend Biotech received 78 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 71.79% of users gave Legend Biotech an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformLegend BiotechOutperform Votes8471.79% Underperform Votes3328.21% EvotecOutperform Votes654.55% Underperform Votes545.45% Which has more risk & volatility, LEGN or EVO? Legend Biotech has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Which has better valuation and earnings, LEGN or EVO? Evotec has higher revenue and earnings than Legend Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$285.14M20.92-$518.25M-$0.95-34.38Evotec$777.05M1.87-$90.82MN/AN/A Do insiders and institutionals have more ownership in LEGN or EVO? 70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer LEGN or EVO? In the previous week, Legend Biotech had 4 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Legend Biotech and 4 mentions for Evotec. Evotec's average media sentiment score of 0.92 beat Legend Biotech's score of 0.43 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LEGN or EVO? Legend Biotech presently has a consensus target price of $80.62, indicating a potential upside of 146.83%. Evotec has a consensus target price of $5.93, indicating a potential upside of 44.36%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Legend Biotech is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is LEGN or EVO more profitable? Evotec has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Evotec's return on equity of 0.00% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-66.92% -29.69% -19.45% Evotec N/A N/A N/A SummaryLegend Biotech and Evotec tied by winning 8 of the 16 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46B$6.35B$5.24B$9.00BDividend YieldN/A2.94%5.13%4.03%P/E RatioN/A5.2665.3814.27Price / Sales1.87334.891,272.1186.92Price / Cash157.4761.4443.8235.97Price / Book1.206.055.324.80Net Income-$90.82M$154.62M$122.68M$224.91M7 Day Performance-5.73%-1.70%-0.21%1.47%1 Month Performance-5.08%2.75%3.72%4.66%1 Year Performance-48.43%2.60%27.18%20.83% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec2.2683 of 5 stars$4.11+1.7%$5.93+44.4%-49.0%$1.46B$777.05M0.005,061Short Interest ↑LEGNLegend Biotech2.5097 of 5 stars$31.60-6.0%$80.62+155.1%-45.5%$5.77B$520.18M-33.261,800Short Interest ↓News CoverageELANElanco Animal Health4.4179 of 5 stars$11.57+1.2%$16.43+42.0%-18.8%$5.72B$4.45B28.939,800CYTKCytokinetics4.3227 of 5 stars$46.28-0.7%$83.64+80.7%-46.6%$5.46B$7.53M-8.60250Analyst ForecastNUVLNuvalent1.797 of 5 stars$71.42-6.8%$112.36+57.3%+2.7%$5.07BN/A-20.5840Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0517 of 5 stars$7.25-0.5%N/A+7.2%$4.98B$7.01B5.9426,300Positive NewsGap DownTGTXTG Therapeutics4.4939 of 5 stars$27.76-3.9%$40.67+46.5%+93.1%$4.32B$264.79M-277.57290Analyst ForecastAnalyst RevisionNews CoverageVKTXViking Therapeutics3.922 of 5 stars$38.61-1.8%$106.75+176.5%+52.4%$4.30BN/A-41.5220Analyst ForecastAXSMAxsome Therapeutics4.6893 of 5 stars$88.47+10.5%$129.43+46.3%+7.5%$4.29B$338.46M-13.55380Analyst RevisionKRYSKrystal Biotech4.8312 of 5 stars$147.78-3.4%$206.67+39.8%+17.8%$4.25B$241.52M83.49229Short Interest ↓OGNOrganon & Co.4.8138 of 5 stars$15.56-1.8%$21.33+37.1%-0.8%$4.01B$6.41B3.0910,000Positive News Related Companies and Tools Related Companies Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Nuvalent Alternatives Grifols Alternatives TG Therapeutics Alternatives Viking Therapeutics Alternatives Axsome Therapeutics Alternatives Krystal Biotech Alternatives Organon & Co. Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
